Skip to main content

bemarituzumab

Generic: FPA144·Code: FPA144

bemarituzumab: sourced relationships with 1 company · 5 clinical trials tracked.

bemarituzumab evidence translation

What we can confirm

What it means

Source-backed records connect bemarituzumab to FPRX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could bemarituzumab → FPRX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors

Related indications

Gastric or gastroesophageal junction (GEJ) cancerGastric CancerSolid Tumors
Dated Pipeline Records (1)
CompanyDated record stage
FIVE PRIME THERAPEUTICS, INC. (FPRX)
licensee · Reported 2020-02-27 · Current development: unknownSource
Gastric or gastroesophageal junction (GEJ) cancer
Phase 3
Clinical Trial Registry Records (5)

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)

NCT05325866Registry updated 2026-06-22·Phase 1/Phase 2·AMGN
Terminated

Primary endpoint: Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)

Interventionalopen260 targetStarted 2022-09Completion 2026-0150 sites · Argentina, Australia, Austria, Belgium…Amgen

A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).

NCT05322577Registry updated 2026-07-29·Phase 1/Phase 2·AMGN
Terminated

Primary endpoint: Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)

Interventionalopen72 enrolledStarted 2022-05Completion 2025-1142 sites · Japan, Singapore, South Korea, Taiwan…Amgen

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

NCT05111626Registry updated 2026-09-10·Phase 3·AMGN
Terminated

Primary endpoint: Part 1: Number of Participants Who Experienced DLTs

InterventionalRandomizeddouble515 enrolledStarted 2022-03Completion 2025-1050 sites · Argentina, Australia, United StatesAmgen

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression

NCT05052801Registry updated 2026-05-27·Phase 3·AMGN
Completed

Primary endpoint: Overall Survival

InterventionalRandomizeddouble547 enrolledStarted 2022-03Completion 2026-0450 sites · Argentina, Australia, Belgium, Brazil…Amgen

FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1

NCT03694522Registry updated 2024-02-28·Phase 2
Completed

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizeddouble155 enrolledStarted 2018-09Completion 2022-0550 sites · Australia, Belgium, China, United StatesFive Prime Therapeutics, Inc.

Frequently asked questions

Which companies have sourced relationships with bemarituzumab?

bemarituzumab has dated SEC/FDA relationship records for FIVE PRIME THERAPEUTICS, INC..

How many clinical trials involve bemarituzumab?

BioSniper tracks 5 clinical trials involving bemarituzumab.